Vyvanse Capsules Specified Drug Use-results Survey (Surveillance regarding pediatric use)

Vyvanse Capsules Specified Drug Use-results Survey (Surveillance regarding pediatric use) - Vyvanse Capsules Specified Drug Use-results Survey (Surveillance regarding pediatric use)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046038

Enrollment

100

Registered

2021-11-15

Start date

2021-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit/hyperactivity disorder

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: AD/HD patients who meet all of the following 1_Not to have experience to use Vyvanse Capsules 2_6-18 years old 3_Pre-dose efficacy in patients has been obtained 4_The consent form about joining this survey has been obtained

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Evaluation of physicians and teachers by the ADHD Rating Scale IV (ADHD-RS-IV) Japanese Version	—

Secondary

Measure	Time frame
Incidence rates of adverse drug reactions, Safety specification items	—

Countries

Japan

Contacts

Public ContactKouji Yamashita

Takeda Pharmaceutical Co., Ltd. PMS Strategic Management, Japan Medical Office

kouji.yamashita@takeda.com+81-80-4324-2955

Outcome results